PERSONAL DE APOYO
CAO Gabriel Fernando
artículos
Título:
Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model
Autor/es:
TOBLLI JE, RIVAS C, CAO G, GIANI JF, FUNK F, MIZZEN L, DOMINICI FP
Revista:
Chemotherapy research and practice
Editorial:
Hindawi Pub. Corp
Referencias:
Lugar: Cairo; Año: 2014 p. 1 - 9
ISSN:
2090-2107
Resumen:
Since anthracycline-induced cardiotoxicity (AIC), a complication of
anthracycline-based chemotherapies, is thought to involve iron, concerns
exist about using iron for anaemia treatment in anthracycline-receiving
cancer patients. This study evaluated how intravenous ferric
carboxymaltose (FCM) modulates the influence of iron deficiency anaemia
(IDA) and doxorubicin (3-5 mg per kg body weight [BW]) on
oxidative/nitrosative stress, inflammation, and cardiorenal function in
spontaneously hypertensive stroke-prone (SHR-SP) rats. FCM was given as
repeated small or single total dose (15 mg iron per kg BW), either
concurrent with or three days after doxorubicin. IDA (after dietary iron
restriction) induced cardiac and renal oxidative stress (markers
included malondialdehyde, catalase, Cu,Zn-superoxide dismutase, and
glutathione peroxidase), nitrosative stress (inducible nitric oxide
synthase and nitrotyrosine), inflammation (tumour necrosis factor-alpha
and interleukin-6), and functional/morphological abnormalities (left
ventricle end-diastolic and end-systolic diameter, fractional
shortening, density of cardiomyocytes and capillaries, caveolin-1
expression, creatinine clearance, and urine neutrophil
gelatinase-associated lipocalin) that were aggravated by doxorubicin.
Notably, iron treatment with FCM did not exacerbate but attenuated the
cardiorenal effects of IDA and doxorubicin independent of the iron
dosing regimen. The results of this model suggest that intravenous FCM
can be used concomitantly with an anthracycline-based chemotherapy
without increasing signs of AIC.